LENZ Therapeutics (NASDAQ:LENZ) Research Coverage Started at TD Cowen

TD Cowen began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research report released on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $60.00 target price on the stock.

LENZ Therapeutics Stock Up 3.1 %

Shares of NASDAQ:LENZ opened at $26.30 on Tuesday. The business’s 50-day moving average is $24.09 and its 200 day moving average is $27.01. LENZ Therapeutics has a 1 year low of $14.42 and a 1 year high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, equities research analysts predict that LENZ Therapeutics will post -2.18 EPS for the current year.

Institutional Investors Weigh In On LENZ Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in LENZ. Vanguard Group Inc. increased its position in shares of LENZ Therapeutics by 5.3% in the 4th quarter. Vanguard Group Inc. now owns 1,178,447 shares of the company’s stock valued at $34,022,000 after acquiring an additional 59,630 shares during the period. Price T Rowe Associates Inc. MD grew its stake in LENZ Therapeutics by 83.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company’s stock valued at $23,760,000 after purchasing an additional 374,326 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in LENZ Therapeutics during the 4th quarter valued at about $22,243,000. State Street Corp increased its holdings in shares of LENZ Therapeutics by 18.7% in the third quarter. State Street Corp now owns 289,154 shares of the company’s stock valued at $6,865,000 after purchasing an additional 45,600 shares during the period. Finally, Alyeska Investment Group L.P. raised its stake in shares of LENZ Therapeutics by 16.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 142,113 shares of the company’s stock worth $4,103,000 after purchasing an additional 20,000 shares during the last quarter. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.